Adaptive Biotechnologies Corporation (ADPT) Stock Falls on Q4 2025 Earnings

Adaptive Biotechnologies Corporation (ADPT) reported Q4 2025 results. Key operating and profitability metrics included:

Total revenue: $71.7 million (+51.0% year‑over‑year).

Gross profit: $53.5 million (+81.7% year‑over‑year).

Operating loss: $12.8 million (operating loss; -62.3% year‑over‑year).

Net loss attributable to common shareholders: $13.6 million (-59.8% year‑over‑year).

Diluted earnings per share: $(0.09) per share (-60.9% year‑over‑year).

Balance-sheet and cash-flow highlights:

Cash from operating activities: $2.1 million (down 116.5% year‑over‑year).

Purchases of property, plant and equipment (capex): $0.6 million (up 695.0% year‑over‑year).

Cash and cash equivalents: $70.5 million (+47.1% year‑over‑year).

Total liabilities: $287.7 million (down 14.6% year‑over‑year).

Stock reaction: down 4.19% since market close.

The quarter showed strong top-line growth and expanding gross profit, but the company remained unprofitable at both the operating and net levels. Liquidity improved year over year with higher cash balances, while operating cash generation was modest.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Adaptive Biotechnologies Corporation Insider Trading Activity

Adaptive Biotechnologies Corporation insiders have traded $ADPT stock on the open market 25 times in the past 6 months. Of those trades, 0 have been purchases and 25 have been sales.

Here’s a breakdown of recent trading of $ADPT stock by insiders over the last 6 months:

SHARON BENZENO (Chief Commercial Ofc Imm Med) has made 0 purchases and 3 sales selling 619,006 shares for an estimated $10,356,402.
CHAD M ROBINS (CEO and Chairman) has made 0 purchases and 7 sales selling 499,995 shares for an estimated $8,639,608.
FRANCIS LO (Chief People Officer) has made 0 purchases and 4 sales selling 200,999 shares for an estimated $3,311,543.
KYLE PISKEL (Chief Financial Officer) has made 0 purchases and 4 sales selling 169,493 shares for an estimated $3,295,150.
HARLAN S ROBINS (Chief Scientific Officer) has made 0 purchases and 6 sales selling 100,000 shares for an estimated $1,784,220.
ROBERT HERSHBERG sold 22,968 shares for an estimated $367,488

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Adaptive Biotechnologies Corporation Hedge Fund Activity

We have seen 145 institutional investors add shares of Adaptive Biotechnologies Corporation stock to their portfolio, and 151 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RUBRIC CAPITAL MANAGEMENT LP removed 6,256,847 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $93,602,431
WESTFIELD CAPITAL MANAGEMENT CO LP added 4,060,481 shares (+inf%) to their portfolio in Q4 2025, for an estimated $65,942,211
AMERIPRISE FINANCIAL INC removed 3,380,722 shares (-56.6%) from their portfolio in Q4 2025, for an estimated $54,902,925
PRICE T ROWE ASSOCIATES INC /MD/ added 3,299,635 shares (+303.4%) to their portfolio in Q4 2025, for an estimated $53,586,072
INVESCO LTD. added 2,216,595 shares (+248.8%) to their portfolio in Q4 2025, for an estimated $35,997,502
MACQUARIE GROUP LTD removed 2,104,414 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $34,175,683
LORD, ABBETT & CO. LLC added 1,854,355 shares (+151.2%) to their portfolio in Q4 2025, for an estimated $30,114,725

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Adaptive Biotechnologies Corporation Government Contracts

We have seen $517,160 of award payments to $ADPT over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

CLONO-SEQ TESTING.: $243,750
CLONOSEQ FDA-CLEARED IN VITRO DIAGNOSTIC (IVD) TESTING SERVICES: $117,000
CLONOSEQ TESTING FOR BOSTON AND WEST HAVEN VA HCS: $95,000
CLONOSEQ HAS RECEIVED CLEARANCE FROM THE FOOD AND DRUG ADMINISTRATION FOR AN IN VITRO DIAGNOSTIC TEST SERVI...: $44,850
IMMUNOSEQ MMTCRB SERVICE (DEEP), CATALOG# ISS20001, QTY: 16: $16,560

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Adaptive Biotechnologies Corporation Analyst Ratings

Wall Street analysts have issued reports on $ADPT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 11/06/2025
BTIG issued a "Buy" rating on 11/06/2025
Piper Sandler issued a "Overweight" rating on 10/15/2025
Guggenheim issued a "Buy" rating on 09/30/2025

To track analyst ratings and price targets for Adaptive Biotechnologies Corporation, check out Quiver Quantitative's $ADPT forecast page.

Adaptive Biotechnologies Corporation Price Targets

Multiple analysts have issued price targets for $ADPT recently. We have seen 6 analysts offer price targets for $ADPT in the last 6 months, with a median target of $20.5.

Here are some recent targets:

Mark Massaro from BTIG set a target price of $22.0 on 02/06/2026
Sebastian Sandler from JP Morgan set a target price of $21.0 on 02/06/2026
Subbu Nambi from Guggenheim set a target price of $21.0 on 01/26/2026
Tejas Savant from Morgan Stanley set a target price of $16.0 on 11/11/2025
David Westenberg from Piper Sandler set a target price of $20.0 on 10/15/2025